Solid tumours with confirmed NTRK gene fusion Program in Pharmaceutical Benefits Scheme (PBS) 012-22062457
This document outlines details of PBS-subsidised larotrectinib for patients with solid tumours with confirmed neurotrophic tropomyosin receptor kinase (NTRK) gene fusion.
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings.